Navigation Links
Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Combination Study of MM-121 and Multiple Anticancer Therapies in Patients with Advanced Solid Tumors
Date:11/30/2011

CAMBRIDGE, Mass., Nov. 30, 2011 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a Phase 1 clinical study combining MM-121, a fully human monoclonal antibody that targets ErbB3, with one of multiple standard treatment regimens for patients with advanced solid tumors.

(Logo: http://photos.prnewswire.com/prnh/20100913/NE63515LOGO)

The Phase 1 study evaluates the safety and pharmacokinetics of MM-121 when administered in combination with these separate chemotherapy regimens. Study sites in North America and the European Union are expected to participate in this trial.  The first patient was enrolled at Fox Chase Cancer Center in Philadelphia, PA.

Merrimack entered into an exclusive, global collaboration and licensing agreement with Sanofi for MM-121 in 2009.

About Merrimack

Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. Merrimack applies Network Biology, its proprietary systems biology-based approach to biomedical research, throughout the research and development process.  Merrimack currently has four targeted therapeutic oncology candidates in clinical development and a fifth expected to enter clinical development by early 2012.

Contact:  Kathleen Petrozzelli Gallagher, Corporate Communications, Merrimack, 617-441-1043, kgallagher@merrimackpharma.com

Betsy Stevenson, RaymondStevenson Healthcare Communications, 860-984-1424, betsy@raymondstevenson.com


'/>"/>
SOURCE Merrimack Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
2. Sanofi-aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM-121, an Anti-ErbB3 Monoclonal Antibody
3. Merrimack Pharmaceuticals to Present at the 2010 Stifel Nicolaus Healthcare Conference
4. Merrimack Pharmaceuticals Announces the Addition of Michael Porter to its Board of Directors
5. Merrimack Pharmaceuticals Announces that Recruitment is Open in a Phase 1 Combination Study of MM-111 with Multiple Treatment Regimens in HER2 Positive Patients
6. FDA Grants Orphan Drug Status to Merrimack Pharmaceuticals MM-398, a Nanotherapeutic Encapsulation of Irinotecan, for the Treatment of Pancreatic Cancer
7. Merrimack Pharmaceuticals Initiates Enrollment in a Neoadjuvant Phase 2 Study of MM-121 with Paclitaxel in HER2-negative Breast Cancer Patients
8. Multiple Programs from Merrimack Pharmaceuticals Pipeline to be Presented at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
9. Merrimack Pharmaceuticals Initiates Enrollment in Phase 2 Study of MM-121 in Combination with Erlotinib in Three Groups of Patients with Non-Small Cell Lung Cancer
10. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... DUBLIN and RALEIGH, N.C. ... subsidiary of Endo International plc (NASDAQ: ENDP ... BDSI ) announced today that they have ... Buccal Film to the U.S. Food and Drug Administration ... the management of pain severe enough to require daily, ...
(Date:12/22/2014)... Apnea Sciences ( www.apneasciences.com ) announced it ... Aliso Viejo , California.  Jimmy Fallon , ... and worldwide expansion, a new facility with expanded infrastructure ... snore cure have exceeded our expectations and thus required ... in 23 countries and will be increasing to 39 ...
(Date:12/22/2014)... LUXEMBOURG , Dec. 22, 2014  ConvaTec, a ... Paul Moraviec has been appointed Interim Chief Executive Officer ... Mr. Moraviec succeeds Ken Berger .  "The Board ... service in leading ConvaTec over the past three years," ... Board of Directors.  "We are confident that the company ...
Breaking Medicine Technology:Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2
... , NASHVILLE, Tenn., Oct. 27 Cumberland Pharmaceuticals Inc. ... report third quarter 2009 financial results before the market opens ... live Internet webcast will be held on Tuesday, November 10, ... , To participate on the call, please dial 888-417-8462 (for ...
... Denver ophthalmologist recently became the first in Colorado to implant ... bar for patient care in the state while increasing the ... director of Cutarelli Vision in Denver and Fort Collins, said ... eye of a 70-year-old man whose cataracts in his left ...
Cached Medicine Technology:Cumberland Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 10, 2009 2Denver-Ft. Collins Ophthalmologist First in Colorado to Implant nanoFLEX Lens 2Denver-Ft. Collins Ophthalmologist First in Colorado to Implant nanoFLEX Lens 3
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. 24, 2014 ... can receive effective, less expensive care from a clinic that ... team of dedicated health care professionals, a new study shows. ... need either hospitalization or a trip to the emergency room ... at the University of Texas in Houston versus usual care, ...
(Date:12/25/2014)... Dennis Thompson HealthDay Reporter ... could be closing in on a "fountain of youth" drug ... health of older adults, a new study suggests. Seniors ... a drug that targets a genetic signaling pathway linked to ... report. The experimental medication, a version of ...
(Date:12/25/2014)... Viejo, California (PRWEB) December 25, 2014 ... release of ProFire 5k. A fully customizable business presentation ... . , “Adding the ProFire 5k business tool, users ... Said Christina Austin, CEO of Pixel Film Studios. “ProFire ... look and style to add professionalism to a presentation” ...
(Date:12/24/2014)... AlignLife of Wauwatosa loves helping those in ... the holiday season, AlignLife looks forward to their annual toy ... Sara Mahalko-Leonhardt, owner of AlignLife. "It brings our patients as ... are able to give kids toys for Christmas who would ... generosity of our patients." , The 70 toys were donated ...
(Date:12/24/2014)... 25, 2014 Recently, iFitDress.com, a famous dress ... prom dresses under $150 . All these items are brand ... website has already been updated with the new range of ... ordered so far. All iFitDress.com’s designs are made according to ... using great materials. Every outfit from the company is handpicked ...
Breaking Medicine News(10 mins):Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:AlignLife of Wauwatosa Brings Joy to Less Fortunate Families 2Health News:Many Prom Dresses under 150 from Well-known Dress Manufacturer iFitDress.com 2
... Dec. 11 Emerging Growth Equities, Ltd. initiates coverage ... BUY rating and a $9.00 price target. PolyMedix ... serious, life-threatening acute disorders. The Company,s leading clinical ... antagonist PMX-60056. , , ...
... training to ease their lower back pain are better off ... jogging, according to a University of Alberta study. , The ... a 60 per cent improvement in pain and function levels ... 16-week exercise program of resistance training using dumbbells, barbells and ...
... Nutritional Supplements,has developed a new revolutionary appetite and weight ... their desire to eat,and reduce their food intake, it ... less but still feel satisfied. Additionally, Trimma(TM),comes in an ... their chocolate and sweet cravings. , ...
... nation is facing, call center outsourcing services provider Outsourcing City remains ... to further save on its investments, the company is now offering ... telemarketing services. , ... Brea, CA (PRWEB) December 11, ...
... Human Immunology Center (RHIC) has been awarded a $4 ... of Allergy and Infection Disease (NIAID). The renewal enables ... a worldwide effort to standardize how researchers use complex ... discovery of new treatments. , When standardization ...
... Dec. 11 Intellx Inc. announces a 50%,price cut ... Intellx is one of four major condom makers ... USA, Inspiral(R). , ... Brian,Osterberg, "and the coalescence of growing popularity of our ...
Cached Medicine News:Health News:Emerging Growth Equities, Ltd. Initiates Coverage of PolyMedix Inc. With a Buy Rating and a $9.00 Price Target 2Health News:Trimma(TM) Now Available in the United States for People Looking for a Delicious Way to Control Their Calories 2Health News:Free Trial of Call Center Outsourcing Services and Performance Based Telemarketing from Outsourcing City 2Health News:Free Trial of Call Center Outsourcing Services and Performance Based Telemarketing from Outsourcing City 3Health News:Immunology Center will continue to drive standard methods, better science 2Health News:Immunology Center will continue to drive standard methods, better science 3Health News:Immunology Center will continue to drive standard methods, better science 4Health News:Immunology Center will continue to drive standard methods, better science 5Health News:Intellx Bails Out Safe Sex 2
... IMMULITE 2000 assays are ... the IMMULITE 2000, a ... immunoassay analyzer. IMMULITE 2000 ... centralization, and a rapidly ...
... CARDIAC M Myoglobin assay for use ... The Cardiac reader analyzer is a ... include: always ready to use (stand-by ... batch specific data entered automatically using ...
IRMA kit for detection of the cardiac marker Myoglobin...
... The CALBIOTECH INC. (CBI) Prolactin ELISA kit ... prolactin in human serum or plasma. Human ... polypeptide hormone with a molecular weight of ... based on a solid phase direct sandwich ...
Medicine Products: